These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 33139246)

  • 1. Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma.
    Patel V; Elias R; Formella J; Schwartzman W; Christie A; Cai Q; Malladi V; Kapur P; Vazquez M; McKay R; Pedrosa I; Hannan R; Hammers H; Brugarolas J
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33139246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
    Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
    BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors associated granulomatous small vessel vasculitis accompanied with tubulointerstitial nephritis: a case report.
    Tominaga K; Takeuchi K; Takakuma S; Sakamoto E; Hatanaka S; Kajimoto Y; Toda E; Terasaki Y; Kunugi S; Terasaki M; Shimizu A
    BMC Nephrol; 2023 Mar; 24(1):48. PubMed ID: 36894873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
    Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
    J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy: Single Center Experience of Management and Drug Rechallenge.
    Manohar S; Ghamrawi R; Chengappa M; Goksu BNB; Kottschade L; Finnes H; Dronca R; Leventakos K; Herrmann J; Herrmann SM
    Kidney360; 2020 Jan; 1(1):16-24. PubMed ID: 35372854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute tubulointerstitial nephritis and IgM deposits on glomerular capillary walls after immunotherapy with nivolumab for metastatic renal cell carcinoma.
    Irifuku T; Satoh A; Tani H; Mandai K; Masaki T
    CEN Case Rep; 2020 Feb; 9(1):48-54. PubMed ID: 31605271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephrotic syndrome with acute kidney injury due to combination therapy of immune checkpoint inhibitors: a case report and review of the literature.
    Saiki R; Katayama K; Saiki H; Fukumori A; Tsujimoto K; Yamawaki M; Tanaka F; Takahashi D; Oda K; Suzuki Y; Murata T; Dohi K
    BMC Nephrol; 2024 Feb; 25(1):51. PubMed ID: 38336610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma.
    Yin J; Elias R; Peng L; Levonyak N; Asokan A; Christie A; Kubiliun N; Brugarolas J; Hammers HJ
    Clin Genitourin Cancer; 2022 Jun; 20(3):260-269. PubMed ID: 35277350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
    Sise ME; Seethapathy H; Reynolds KL
    Oncologist; 2019 Jun; 24(6):735-742. PubMed ID: 30902916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
    Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
    J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma.
    Ratanasrimetha P; Reddy VD; Kala J; Tchakarov A; Glass WF; Msaouel P; Lin JS
    Front Immunol; 2022; 13():898811. PubMed ID: 35967405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two acute kidney injury episodes after ICI therapy: a case report.
    Ishiga K; Kobayashi R; Kanaoka T; Harada J; Kato I; Fujii S; Wakui H; Toya Y; Tamura K
    CEN Case Rep; 2024 Oct; 13(5):408-415. PubMed ID: 38453804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis.
    Qualls D; Seethapathy H; Bates H; Tajmir S; Heidari P; Endres P; Reynolds K; Lawrence D; Sise M
    J Immunother Cancer; 2019 Dec; 7(1):356. PubMed ID: 31864416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
    Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors.
    Rahma OE; Reuss JE; Giobbie-Hurder A; Shoja E Razavi G; Abu-Shawer O; Mehra P; Gupta S; Simon R; Khleif SN
    Clin Cancer Res; 2021 Jan; 27(2):485-491. PubMed ID: 33082209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durable response after immunotherapy discontinuation for delayed and severe immune-related adverse events: a case report.
    Pesola G; Murianni V; Rebuzzi SE; Banna GL; Cerbone L; Catalano F; Borea R; Gandini A; Cremante M; Puglisi S; Trovato F; Fornarini G
    Immunotherapy; 2021 Dec; 13(17):1379-1386. PubMed ID: 34743545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
    Gul A; Stewart TF; Mantia CM; Shah NJ; Gatof ES; Long Y; Allman KD; Ornstein MC; Hammers HJ; McDermott DF; Atkins MB; Hurwitz M; Rini BI
    J Clin Oncol; 2020 Sep; 38(27):3088-3094. PubMed ID: 32491962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab.
    Ishihara H; Takagi T; Kondo T; Homma C; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Urol Oncol; 2019 Jun; 37(6):355.e21-355.e29. PubMed ID: 30935847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis.
    Sise ME; Wang Q; Seethapathy H; Moreno D; Harden D; Smith RN; Rosales IA; Colvin RB; Chute S; Cornell LD; Herrmann SM; Fadden R; Sullivan RJ; Yang NJ; Barmettler S; Wells S; Gupta S; Villani AC; Reynolds KL; Farmer J
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.